JP2013513377A5 - - Google Patents

Download PDF

Info

Publication number
JP2013513377A5
JP2013513377A5 JP2012542587A JP2012542587A JP2013513377A5 JP 2013513377 A5 JP2013513377 A5 JP 2013513377A5 JP 2012542587 A JP2012542587 A JP 2012542587A JP 2012542587 A JP2012542587 A JP 2012542587A JP 2013513377 A5 JP2013513377 A5 JP 2013513377A5
Authority
JP
Japan
Prior art keywords
identity
functionally equivalent
component
equivalent variant
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012542587A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013513377A (ja
JP5784626B2 (ja
Filing date
Publication date
Priority claimed from ES200931158A external-priority patent/ES2362062B1/es
Application filed filed Critical
Priority claimed from PCT/ES2010/070818 external-priority patent/WO2011070214A2/es
Publication of JP2013513377A publication Critical patent/JP2013513377A/ja
Publication of JP2013513377A5 publication Critical patent/JP2013513377A5/ja
Application granted granted Critical
Publication of JP5784626B2 publication Critical patent/JP5784626B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012542587A 2009-12-11 2010-12-10 免疫療法および抗腫瘍治療のための新規な結合体および組成物 Expired - Fee Related JP5784626B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ESP200931158 2009-12-11
ES200931158A ES2362062B1 (es) 2009-12-11 2009-12-11 Nuevos conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral.
ES201030813 2010-05-27
ESP201030813 2010-05-27
PCT/ES2010/070818 WO2011070214A2 (es) 2009-12-11 2010-12-10 Conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral

Publications (3)

Publication Number Publication Date
JP2013513377A JP2013513377A (ja) 2013-04-22
JP2013513377A5 true JP2013513377A5 (zh) 2014-01-30
JP5784626B2 JP5784626B2 (ja) 2015-09-24

Family

ID=43927978

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012542587A Expired - Fee Related JP5784626B2 (ja) 2009-12-11 2010-12-10 免疫療法および抗腫瘍治療のための新規な結合体および組成物

Country Status (11)

Country Link
US (1) US8771664B2 (zh)
EP (1) EP2511294B1 (zh)
JP (1) JP5784626B2 (zh)
CN (1) CN102753574B (zh)
AU (1) AU2010329805B2 (zh)
BR (1) BR112012013868A8 (zh)
CA (1) CA2783876C (zh)
ES (1) ES2463016T3 (zh)
MX (1) MX2012006691A (zh)
RU (1) RU2597989C2 (zh)
WO (1) WO2011070214A2 (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2824515C (en) 2011-01-18 2022-09-13 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
WO2015089217A2 (en) 2013-12-10 2015-06-18 Bionz, Llc Methods of developing selective peptide antagonists
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
EP2986312B1 (en) * 2013-04-19 2021-12-15 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
WO2015054701A2 (en) * 2013-10-13 2015-04-16 Nova Southeastern University Analyzing immune signaling networks for identification of therapeutic targets in complex chronic medical disorders, identification of a natural killer cell population as a potential therapeutic target for gulf war illness & myalgic encephalomyelitis/chronic fatigue syndrome, and modulation of natural killer cell function by stimulation with interleukin 15
HUE057917T2 (hu) * 2014-01-15 2022-06-28 Kadmon Corp Llc Immunmodulátor szerek
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
US10464982B2 (en) 2014-04-23 2019-11-05 Emory University Compositions of GM-CSF and interleukin fusions for immune modulation and uses related thereto
US20180155439A1 (en) * 2015-06-10 2018-06-07 Emory University Compositions and Conjugates Comprising an Interleukin and Polypeptides That Specifically Bind TGF-beta
CN106317225A (zh) * 2015-06-28 2017-01-11 复旦大学 具有靶向性长效白细胞介素22融合蛋白及其制备方法和用途
US11400134B2 (en) 2015-10-09 2022-08-02 Bioniz, Llc Modulating gamma-c-cytokine activity
EP3443001A4 (en) 2016-04-11 2020-04-29 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
CA3029813A1 (en) 2016-06-13 2017-12-21 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
US11524033B2 (en) 2017-09-05 2022-12-13 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
EP3727146A4 (en) * 2017-12-19 2021-10-06 Blaze Bioscience, Inc. CELL PENETRATION PEPTIDE TUMOR AND IMMUNO-ONCOLOGY ADDRESSING AGENT COMPLEXES AND METHODS OF USE
WO2023064469A1 (en) * 2021-10-13 2023-04-20 Modernatx, Inc. Compositions of mrna-encoded il15 fusion proteins and methods of use thereof
US20240043499A1 (en) * 2022-08-07 2024-02-08 Protean Bio, Inc. Peptides for beta-cell survival and insulin production

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6408586A (en) * 1985-10-03 1987-04-24 Biotechnology Research Partners Limited Novel lipoprotein-based drug-delivery systems
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
US5747024A (en) 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
AU720201B2 (en) 1995-03-08 2000-05-25 Scripps Research Institute, The Antigen presenting system and methods for activation of T-cells
US6787154B2 (en) 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
EP2343317A1 (en) 2000-11-10 2011-07-13 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
AU2008201887B2 (en) * 2000-11-10 2011-06-30 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
EP1718282A4 (en) 2004-01-15 2010-07-14 Sinai School Medicine PROCESS AND COMPOSITIONS FOR IMAGE PRESENTATION
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
US20060257361A1 (en) 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
WO2007069090A2 (en) 2005-12-06 2007-06-21 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
US9139611B2 (en) 2006-07-13 2015-09-22 Novozymes Biopharma Dk A/S Process for preparing particles of proteinaceous material
KR100817024B1 (ko) 2006-11-09 2008-03-26 재단법인 목암생명공학연구소 핵산 또는 약물을 간에 특이적으로 전달하는 복합체 및이를 포함하는 약학적 조성물
MX2010013759A (es) 2008-06-13 2011-05-25 Proyecto Biomedicina Cima Sl Conjugados para la administracion de compuestos biologicamente activos.

Similar Documents

Publication Publication Date Title
JP2013513377A5 (zh)
RU2012129208A (ru) Конъюгаты и композиции для иммунотерапии и противоопухолевого лечения
HRP20190799T1 (hr) Imunocitokini na bazi il-15 i sushi domene il-15r alfa
CN107847583A (zh) 用于治疗癌症的聚乙二醇化白细胞介素‑10
JP2019506843A5 (zh)
JP2013541335A5 (zh)
JP2017532045A5 (zh)
JP2019511222A5 (zh)
RU2016101711A (ru) Высокостабильный т-клеточный рецептор и способ его получения и применения
JP2009506762A5 (zh)
JP2017018125A5 (zh)
JP2017525336A5 (zh)
JP2014500868A (ja) 癌及び慢性感染の治療のための作動薬活性を有するｉｌ−２由来のポリペプチド
JP2011502479A5 (zh)
JP2014523238A5 (zh)
JP2010516290A5 (zh)
FI3642340T3 (fi) Muunneltu l-asparaginaasi
CN107001438A (zh) 白细胞介素‑15组合物及其用途
JP2014510519A5 (zh)
JP2010506826A5 (zh)
JP2013515745A5 (zh)
JP2015522264A5 (zh)
RU2009104749A (ru) Рекомбинантные белки, подобные человеческому интреферону
JP2019530441A5 (zh)
JP2017529326A5 (zh)